In-vitro/in-vivo studies of the biodegradable poly-(d,l-lactide-co- glycolide) microspheres of a novel luteinizing hormone-releasing hormone antagonist for prostate cancer treatment

Anti-Cancer Drugs

Volumn 22, Issue 3, 2011, Pages 262-272

  Du, Lina ^a,b   Mei, Xingguo ^b   Wang, Chenyun ^c   Li, Xin ^c   Zhang, Fucheng ^d   Jin, Yiguang ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d AIR FORCE GENERAL HOSPITAL   (China)

Author keywords

anticancer; luteinizing hormone releasing hormone antagonist; microspheres; poly(d,l lactide co glycolide); testosterone

Indexed keywords

GONADORELIN ANTAGONIST; LXT 101; MACROGOL 6000; MICROSPHERE; POLYGLACTIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DEGRADATION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG FORMULATION; DRUG RELEASE; EMULSION; HISTOPATHOLOGY; HORMONE DETERMINATION; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; RAT; SEMINAL VESICLE; TESTIS;

ANIMALS; ANTINEOPLASTIC AGENTS; DIOXANES; DRUG DELIVERY SYSTEMS; GONADOTROPIN-RELEASING HORMONE; HUMANS; LACTIC ACID; MALE; MICROSPHERES; OLIGOPEPTIDES; ORCHIECTOMY; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; POLYMERS; PROSTATE; PROSTATIC NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, LHRH; TESTIS; TESTOSTERONE;

EID: 79951605326     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283425c2a     Document Type: Article

References (36)

1. Weckermann D, Harzmann R. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur Urol 2004; 46:279-284. (Pubitemid 39078560)
2. Stricker HJ. Luteinizing hormone-releasing hormone antagonists in prostate cancer. Urology 2001; 58:24-27. (Pubitemid 32743402)
3. Lizio R, Klenner T, Borchard G, Romeis P, Sarlikiotis AW, Reissmannb T, et al. Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats. Eur J Pharm Sci 2000; 2000:253-258.
4. Erb K, Klipping C, Duijkers I, Pechstein B, Schueler A, Hermann R. Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women. Fertil Steril 2001; 75:316-323. (Pubitemid 32112108)
5. Niwa M, Enomotoa K, Yamashita K. Measurement of the novel decapeptide cetrorelix in human plasma and urine by liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B 1999; 729:245-253. (Pubitemid 29264130)
6. Beer TM, Garzotto M, Eilers KM, Lemmon D, Wersinger EM. Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing afterorchiectomy. Urology 2004; 63:342-347. (Pubitemid 38234432)
7. McLeod D, Zinner N, Tomera K, Gleason D, Fotheringham N, Campion M, et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001; 58:756-761.
8. Koch M, Steidle C, Brosman S, Centeno A, Gaylis F, Campion M, et al. An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists. Urology 2003; 62:877-882. (Pubitemid 37421235)
9. Gustofson RL, Segars JH, Larsen FW. Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome. Hum Reprod 2006; 21:2830-2837. (Pubitemid 44566994)
10. Mart́inez F, Clua E, Parera N, Rodŕiguez I, Boada M, Coroleu B. Prospective, randomized, comparative study of leuprorelin+ human menopausal gonadotropins versus ganirelix + recombinant follicle-stimulating hormone in oocyte donors and pregnancy rates among the corresponding recipients. Gynecol Endocrinol 2008; 24:188-193. (Pubitemid 351481775)
11. Xiao S. LHRH-antagonists. WO1992008733. 1992
12. Lee VHL. Enzymatic barriers to peptide and protein absorption. CRC Crit Rev Ther Drug Carrier Syst 1988; 5:69-97.
13. Langer R. New methods of drug delivery. Science 1990; 249:1527-1533.
14. Ubaidulla U, Khar RK, Ahmad FJ, Sultana Y, Panda AK. Development and characterization of chitosan succinate microspheres for the improved oral bioavailability of insulin. J Pharm Sci 2007; 96:3010-3023. (Pubitemid 350221200)
15. Boonsongrit Y, Abe H, Sato K, Naito M, Yoshimura M, Ichikawa H, et al. Controlled release of bovine serum albumin from hydroxyapatite microspheres for protein delivery system. Mater Sci Engineering B 2008; 148:162-165. (Pubitemid 351215837)
16. Sun Y, Wang B, Wang H, Jiang J. Controllable preparation of magnetic polymer microspheres with different morphologies by miniemulsion polymerization. J Colloid Interface Sci 2007; 308:332-336.
17. Ito F, Fujimori H, Honnami H, Kawakami H, Kanamura K, Makino K. Effect of polyethylene glycol on preparation of rifampicin-loaded PLGA microspheres with membrane emulsification technique. Colloids Surf B Biointerfaces 2008; 66:65-70.
18. Brandhonneur N, Chevanne F, Vié V, Frisch B, Primault R, Potier M-FL, et al. Specific and non-specific phagocytosis of ligand-grafted PLGA microspheres by macrophages. Eur J Pharm Sci 2009; 36:474-485.
19. Ribeiro-Costa RM, Cunha MRD, Gongora-Rubio MR, Michaluart-Júnior P, Ré MI. Preparation of protein-loaded-PLGA microspheres by an emulsion/solvent evaporation process employing LTCC micromixers. Powder Tech 2009; 190:107-111.
20. Bae SE, Son JS, Park K, Han DK. Fabrication of covered porous PLGA microspheres using hydrogen peroxide for controlled drug delivery and regenerative medicine. J Controlled Release 2009; 133:37-43.
21. Couvreur P, Puisieux F. Nano-and microparticles for the delivery of polypeptides and proteins. Adv Drug Delivery Rev 1993; 10:141-162. (Pubitemid 23172580)
22. Shive M, Anderson J. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Delivery Rev 1997; 28:5-24. (Pubitemid 27497671)
23. Okada H. One-and three-month release injectable microspheres of the LHRH superagonist leuprorelin acetate. Adv Drug Delivery Rev 1997; 28:43-70. (Pubitemid 27497673)
24. Schwach G, Oudry N, Giliberto J-P, Broqua P, Lück M, Lindner H, et al. Biodegradable PLGA microparticles for sustained release of a new GnRH antagonist: part II in vivo performance. Eur J Pharm Biopharm 2004; 57:441-446. (Pubitemid 38490560)
25. Du L, Cheng J, Chi Q, Qie J, Liu Y, Mei X. Biodegradable PLGA microspheres as a sustained release system for a new luteinizing hormone-releasing hormone (LHRH) antagonist. Chem Pharm Bull 2006; 54:1259-1265. (Pubitemid 44351517)
26. Leo E, Scatturin A, Vighi E, Dalpiaz A. Polymeric nanoparticles as drug controlled release systems: a new formulation strategy for drugs with small or large molecular weight. J Nanosci Nanotechnol 2006; 6:3070-3079. (Pubitemid 44579984)
27. Danhier F, Lecouturier N, Vroman B, Jérôme C, Marchand-Brynaert J, Feron O, et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release 2009; 133:11-17.
28. Ravivarapua HB, Burtonb K, DeLucac PP. Polymer and microsphere blending to alter the release of a peptide from PLGA microspheres. Eur J Pharm Biopharm 2000; 50:263-270.
29. Makino K, Arakawa M, Kondo T. Preparation and in vitro degradation properties of polylactide microcapsules. Chem Pharm Bull 1985; 33: 1195-1201. (Pubitemid 15104072)
30. Malmusi S, La Marca A, Giulini S, Xella S, Tagliasacchi D, Marsella T, et al. Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation. Fertil Steril 2005; 84:402-406. (Pubitemid 41125261)
31. Csernus V, Szende B, Schally A. Release of peptides from sustained delivery (microcapsules and microparticles) in vivo. A histological and immunohistochemical study. Int J Peptide Protein Res 1990; 35:557-565. (Pubitemid 20324205)
32. Mäder K, Bittner B, Li Y, Wohlauf W, Kissel T. Monitoring microviscosity and microacidity of the albumin microenvironment inside degrading microparticles from poly(lactide-co-glycolide) (PLG) or ABA-triblock polymers containing hydrophobic poly(lactide-co-glycolide) A blocks and hydrophilic poly(ethyleneoxide) B blocks. Pharm Res 1998; 15:787-793. (Pubitemid 28275659)
33. Makino K, Ohshima H, Kondo T. Effects of plasma proteins on degradation properties of poly(l-lactide) microcapsules. Pharm Res 1987; 4:62-65. (Pubitemid 17050746)
34. Makino K, Ohshima H, Kondo T. Potential distribution across a plasma protein-coated poly(l-lactide) microcapsule surface. J Microencapsul 1990; 7:199-208. (Pubitemid 20224140)
35. Chi X, Zhou W, Cheng J, Zhang Y, Liu K. In vivo characterization of a novel GnRH (gonadotropin-releasing hormone) antagonist, LXT-101, in normal male rats. Reg Peptides 2006; 136:122-129.
36. Kong A, Zhang Z, Qiao J, Zhang F, Zhou W, Liang K, et al. Determination of decapeptide LXT-101 in plasma by HPLC-MS/MS and its pharmacokinetics in beagle dogs. Acta Pharm Sin 2008; 43:946-950.